

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普 华 和 顺 集 团 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

OVERSEAS REGULATORY ANNOUNCEMENT RESULTS OF A SUBSIDIARY

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Sichuan Rekind Medtec., Inc. (also known as Sichuan Ruijian Medical Technology Co. Ltd.) (四川睿健醫療科技股份有限公司) (NEEQ stock code: 874652) (“**Sichuan Ruijian Medical**”), a non-wholly owned subsidiary of PW Medtech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), has announced its unaudited first quarterly report for financial year 2025 on the designated disclosure platform of the National Equities Exchange and Quotation System (“**NEEQS**”) (www.neeq.com.cn). The financial statements of Sichuan Ruijian Medical have been prepared in conformity with China Accounting Standards for Business Enterprises.

A summary of the unaudited financial results of Sichuan Ruijian Medical for the first quarter of 2025 is provided below.

INCOME STATEMENT

	For the three months ended March 31, 2025 (RMB) (Unaudited)	For the three months ended March 31, 2024 (RMB) (Unaudited)	Period-over period change
Revenue	145,036,095.85	100,795,561.06	43.89%
Profit before tax	42,782,684.84	36,580,011.40	16.96%
Income tax	7,907,209.39	5,346,537.17	47.89%
Profit for the year	34,875,475.45	31,233,474.23	11.66%
Profit attributable to the shareholders of Sichuan Ruijian Medical	36,171,069.91	31,269,046.40	15.68%

BALANCE SHEET

	As of March 31, 2025 (RMB) (Unaudited)	As of March 31, 2024 (RMB) (Unaudited)
Total Assets	976,332,617.13	938,433,223.10
Total Liabilities	72,835,020.83	77,390,272.63
Total Equity	903,497,596.30	861,042,950.47

Sichuan Ruijian Medical's revenue during the first quarter of 2025 increased by 43.89% compared to the same period last year. This was primarily due to Sichuan Ruijian Medical's continuous efforts in expanding domestic and overseas markets, the gradual increase in brand awareness of its products, the enhanced market competitiveness and growth in demand.

On April 28, 2025, Sichuan Ruijian Medical received the "Review Inquiry Letter on Sichuan Ruijian Medical Technology Co. Ltd.'s Application for Public Stock Issuance and Listing on the Beijing Stock Exchange" issued by the Beijing Stock Exchange. Sichuan Ruijian Medical, along with the sponsor and other intermediaries, is currently working on responding to the inquiry letter.

GENERAL INFORMATION

The Company is an exempted company incorporated under the laws of the Cayman Islands with limited liability on May 13, 2011. The principal business activity of the Company is investment holding. The Group is principally engaged in the research and development ("R&D"), manufacturing and sales of (i) advanced infusion set, intravenous cannula products, insulin needles etc., (ii) blood purification medical devices, and (iii) animal-derived regenerative medical biomaterial and human tissue repair alternative products in the People's Republic of China (the "PRC").

Sichuan Ruijian Medical is a joint stock limited liability company established in the PRC on August 6, 2013, the shares of which are quoted on the NEEQS (NEEQ stock code: 874652). Sichuan Ruijian Medical is a medical device company, principally engaged in the R&D, manufacturing and sales of medical device for blood purification.

Shareholders of the Company should note that the above unaudited financial results pertain only to Sichuan Ruijian Medical. The unaudited financial results will be consolidated in the accounts of the Company after adjustments in accordance with all applicable Hong Kong Financial Reporting Standards. Public investors and shareholders of the Company should exercise caution when dealing in its securities.

By order of the Board
PW Medtech Group Limited
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, April 30, 2025

As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.